Automated radiofluorination of HER2 single domain antibody: the road towards the clinical translation of [18F]FB-HER2 sdAb
Abstract Background With the next generation of Human Epidermal Growth Factor Receptor 2 (HER2) -targeting therapies, such as antibody–drug conjugates, showing benefit in “HER2 low” and even “HER2 ultralow” patients, the need for novel methods to quantify HER2 expression accurately becomes even more...
Saved in:
| Main Authors: | Herlinde Dierick, Laurent Navarro, Sonja Van den Block, Jelena Saliën, Tony Lahoutte, Vicky Caveliers, Jessica Bridoux |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-11-01
|
| Series: | EJNMMI Radiopharmacy and Chemistry |
| Online Access: | https://doi.org/10.1186/s41181-024-00306-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01) -
Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
by: Yoonwon Kook, et al.
Published: (2024-11-01) -
Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer
by: Taeyeong Kim, et al.
Published: (2025-01-01) -
Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
by: Yoonwon Kook, et al.
Published: (2024-11-01) -
HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.
by: Samar M Alanazi, et al.
Published: (2023-01-01)